Third - your input is appreciated here, based on what I just read in the abstracts -
GS-7997 in GT1 patients w Rib has an SVR4 of 88%. They are not disclosing the SVR12 data but are committing to disclose it at the meeting.
Telaprevir / Rib / VX-222 has an SVR4 of 91% and an SVR12 of 83%.
They make some qualifications on the Vertex data and I don't know if I am comparing apples to oranges - however, the Gilead data did show a discomforting level of relapse on the all oral trials in all genotypes. My takeaway is that while the drugs are effective in knocking the virus down, the shorter treatment duration's are ineffective in killing it completely. It almost appears to me that a protease / polymerase inhibitor should be dosed for 4 weeks w/ Ribavarin, than dosed with interferon for 4 weeks with the 3 drug regimen based on response, than a final 4 weeks of the 3 or 4 drug regimen based on response. Let me know what you think. Thank you.
John, it is very interesting. It is too early to comment on all specific results, but the ELECTRON GS-7977 + RBV trial is NOT impressive. Read the high relapse rates below:
"...... Of the 10 GT 1 prior null responders, 1 achieved SVR12; the other 9 relapsed prior to post-treatment wk 4. Of the 24 treatment-experienced GT 2/3 patients for whom data are available, 18 (75%) achieved SVR4. Two of these patients subsequently relapsed 8 wks after completing therapy for a total of 8 relapses on or before SVR8."
Thanks John and Third for the information. With that said, I'm wondering why investors continue to pump GILD stock -- they hit their 52-week high yesterday. It goes to show (to some extent) that this is about $$ versus the science and the patients. Unbelievable. Perhaps they are setting up ahead of time to cover their potential losses, should the data for GS7977 not be as impressive as previously believed?
AASLD in November will be very interesting.....
Good luck to all!